

Klaus Kopka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9501379/publications.pdf>

Version: 2024-02-01

225
papers

12,980
citations

28190

55
h-index

26548

107
g-index

248
all docs

248
docs citations

248
times ranked

8167
citing authors

#	ARTICLE	IF	CITATIONS
1	Towards Optimized Bioavailability of ^{99m} Tc-Labeled Barbiturates for Non-invasive Imaging of Matrix Metalloproteinase Activity. <i>Molecular Imaging and Biology</i> , 2022, 24, 434-443.	1.3	3
2	Non-Invasive Assessment of Locally Overexpressed Human Adenosine 2A Receptors in the Heart of Transgenic Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1025.	1.8	1
3	Experimental techniques to study protein-surfactant interactions: New insights into competitive adsorptions via drop subphase and interface exchange. <i>Advances in Colloid and Interface Science</i> , 2022, 301, 102601.	7.0	18
4	A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer. <i>Pharmaceuticals</i> , 2022, 15, 267.	1.7	1
5	Development and Biological Evaluation of the First Highly Potent and Specific Benzamide-Based Radiotracer [¹⁸ F]BA3 for Imaging of Histone Deacetylases 1 and 2 in Brain. <i>Pharmaceuticals</i> , 2022, 15, 324.	1.7	0
6	Dual-Labeling Strategies for Nuclear and Fluorescence Molecular Imaging: Current Status and Future Perspectives. <i>Pharmaceuticals</i> , 2022, 15, 432.	1.7	7
7	Automated radiosynthesis of the adenosine A _{2A} receptor-targeting radiotracer [¹⁸ F]FLUDA. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2022, , .	0.5	1
8	“Clickable”-Albumin Binders for Modulating the Tumor Uptake of Targeted Radiopharmaceuticals. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 710-733.	2.9	13
9	Cyclotrons Operated for Nuclear Medicine and Radiopharmacy in the German Speaking D-A-CH Countries: An Update on Current Status and Trends. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	0.7	3
10	Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors. <i>Molecular Pharmaceutics</i> , 2022, 19, 2231-2247.	2.3	5
11	Quantitation of the A _{2A} Adenosine Receptor Density in the Striatum of Mice and Pigs with [¹⁸ F]FLUDA by Positron Emission Tomography. <i>Pharmaceuticals</i> , 2022, 15, 516.	1.7	3
12	Development of Radiotracers for Imaging of the PD-1/PD-L1 Axis. <i>Pharmaceuticals</i> , 2022, 15, 747.	1.7	18
13	Novel Radioiodinated and Radiofluorinated Analogues of FT-2102 for SPECT or PET Imaging of mLDH1 Mutant Tumours. <i>Molecules</i> , 2022, 27, 3766.	1.7	2
14	Structure-Based Design, Optimization, and Development of [¹⁸ F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 9034-9049.	2.9	10
15	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 143-151.	3.3	25
16	Development of the First Potential Nonpeptidic Positron Emission Tomography Tracer for the Imaging of CCR2 Receptors. <i>ChemMedChem</i> , 2021, 16, 640-645.	1.6	5
17	On the consensus nomenclature rules for radiopharmaceutical chemistry “ Reconsideration of radiochemical conversion. <i>Nuclear Medicine and Biology</i> , 2021, 93, 19-21.	0.3	43
18	Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020). <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 5.	1.8	1

#	ARTICLE	IF	CITATIONS
19	The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2057-2058.	3.3	23
20	Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies. <i>Cancer Research</i> , 2021, 81, 2234-2245.	0.4	11
21	Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer. <i>Pharmaceuticals</i> , 2021, 14, 188.	1.7	5
22	Development of an ¹⁸ F-Labeled Irreversible Inhibitor of Transglutaminase 2 as Radiometric Tool for Quantitative Expression Profiling in Cells and Tissues. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3462-3478.	2.9	16
23	Highlight selection of radiochemistry and radiopharmacy developments by editorial board. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 13.	1.8	1
24	Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma. <i>Cancers</i> , 2021, 13, 1508.	1.7	8
25	Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1461-1467.	2.8	9
26	Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA—A Proof of Concept Study. <i>Cancers</i> , 2021, 13, 1974.	1.7	25
27	Development of bispecific theranostic ligand targeting the prostate specific membrane antigen (PSMA) and gastrin releasing peptide (GRPR) receptor. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, S29-S30.	0.3	0
28	The radiolabeling of silicon rhodamines for multimodal PET/ SPECT- and NIR optical imaging. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, S81.	0.3	0
29	¹³¹ Ba as a promising SPECT-diagnostic match for ^{223/224} Radium. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, S95.	0.3	0
30	¹¹ C-Methionine Uptake in the Lactating Human Breast. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, e66-e67.	0.7	0
31	The impact of barium isotopes in radiopharmacy and nuclear medicine — From past to presence. <i>Nuclear Medicine and Biology</i> , 2021, 98-99, 59-68.	0.3	15
32	Synthesis and application of a thiol-reactive HBED-type chelator for development of easy-to-produce Ga-radiopharmaceutical kits and imaging probes. <i>Organic and Biomolecular Chemistry</i> , 2021, 19, 1722-1726.	1.5	10
33	Intraindividual comparison of [68Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. <i>EJNMMI Research</i> , 2021, 11, 109.	1.1	32
34	Radiolabeled Silicon-Rhodamines as Bimodal PET/SPECT-NIR Imaging Agents. <i>Pharmaceuticals</i> , 2021, 14, 1155.	1.7	4
35	Radiolabeled PSMA Inhibitors. <i>Cancers</i> , 2021, 13, 6255.	1.7	22
36	Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. <i>Journal of Nuclear Medicine</i> , 2020, 61, 70-79.	2.8	23

#	ARTICLE	IF	CITATIONS
37	Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management. <i>Journal of Nuclear Medicine</i> , 2020, 61, 46-50.	2.8	26
38	Response Prediction of ¹⁷⁷ Lu-PSMA-617 Radioligand Therapy Using Prostate-Specific Antigen, Chromogranin A, and Lactate Dehydrogenase. <i>Journal of Nuclear Medicine</i> , 2020, 61, 689-695.	2.8	39
39	¹⁸ F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 592-602.	3.3	26
40	Recent Insights in Barium-131 as a Diagnostic Match for Radium-223: Cyclotron Production, Separation, Radiolabeling, and Imaging. <i>Pharmaceuticals</i> , 2020, 13, 272.	1.7	25
41	Live-cell imaging with <i>Aspergillus fumigatus</i> -specific fluorescent siderophore conjugates. <i>Scientific Reports</i> , 2020, 10, 15519.	1.6	13
42	Development of PSMA-1007-Related Series of ¹⁸ F-Labeled Glu-Ureido-Type PSMA Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 10897-10907.	2.9	18
43	Deuteration versus ethylation strategies to improve the metabolic fate of an ¹⁸ F-labeled celecoxib derivative. <i>RSC Advances</i> , 2020, 10, 38601-38611.	1.7	6
44	Rhenium and technetium-complexed silicon rhodamines as near-infrared imaging probes for bimodal SPECT- and optical imaging. <i>Dalton Transactions</i> , 2020, 49, 7294-7298.	1.6	7
45	Synthesis, characterization and evaluation of ⁶⁸ Ga labelled monomeric and dimeric quinazoline derivatives of the HBED-CC chelator targeting the epidermal growth factor receptor. <i>Bioorganic Chemistry</i> , 2020, 100, 103855.	2.0	12
46	Sub-100-nm Radiolabeled Barium Sulfate Nanoparticles as Carriers for Theranostic Applications and Targeted Alpha Therapy. <i>ChemistryOpen</i> , 2020, 9, 797-805.	0.9	16
47	Current Status of PSMA-Radiotracers for Prostate Cancer: Data Analysis of Prospective Trials Listed on ClinicalTrials.gov. <i>Pharmaceuticals</i> , 2020, 13, 12.	1.7	34
48	Automated [¹⁸ F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 18.	1.8	11
49	⁶⁸ Ga, ⁴⁴ Sc and ¹⁷⁷ Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 28.	1.8	19
50	<i>Radiopharmaceutical Sciences</i> , 2020, , 49-191.		2
51	¹⁸ F-Labeled Small-Molecule and Low-Molecular-Weight PET Tracers for the Noninvasive Detection of Cancer. <i>Recent Results in Cancer Research</i> , 2020, 216, 283-318.	1.8	3
52	Detection Efficacy of ¹⁸ F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 362-368.	2.8	238
53	⁶⁸ Ga-PSMA-11 PET/CT in Primary and Recurrent Prostate Carcinoma: Implications for Radiotherapeutic Management in 121 Patients. <i>Journal of Nuclear Medicine</i> , 2019, 60, 234-240.	2.8	49
54	EANM procedure guidelines for radionuclide therapy with ¹⁷⁷ Lu-labelled PSMA-ligands (¹⁷⁷ Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544.	3.3	265

#	ARTICLE	IF	CITATIONS
55	Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. <i>Pharmaceuticals</i> , 2019, 12, 114.	1.7	218
56	Synthesis of a dihalogenated pyridinyl silicon rhodamine for mitochondrial imaging by a halogen dance rearrangement. <i>Beilstein Journal of Organic Chemistry</i> , 2019, 15, 2333-2343.	1.3	6
57	A Multifunctional HBED-Type Chelator with Dual Conjugation Capabilities for Radiopharmaceutical Development. <i>Synlett</i> , 2019, 30, 1795-1798.	1.0	7
58	A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR. <i>Oncoimmunology</i> , 2019, 8, 1659095.	2.1	23
59	HBED-NN: A Bifunctional Chelator for Constructing Radiopharmaceuticals. <i>Journal of Organic Chemistry</i> , 2019, 84, 7501-7508.	1.7	15
60	DNA damage in human whole blood caused by radiopharmaceuticals evaluated by the comet assay. <i>Mutagenesis</i> , 2019, 34, 239-244.	1.0	12
61	Bispecific radioligands targeting prostate-specific membrane antigen and gastrin-releasing peptide receptors on the surface of prostate cancer cells. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 510-522.	0.5	7
62	Impact of ¹⁸ F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1594-1599.	2.8	15
63	Designing tracers for PET imaging of the urokinase-type plasminogen activator receptor from a cyclic uPA-derived peptide: first in vitro evaluations. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 483-494.	0.5	1
64	A new approach to silicon rhodamines by Suzuki-Miyaura coupling – scope and limitations. <i>Beilstein Journal of Organic Chemistry</i> , 2019, 15, 2569-2576.	1.3	4
65	Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors. <i>Cancer Research</i> , 2019, 79, 841-852.	0.4	33
66	Development and dosimetry of ²⁰³ Pb/ ²¹² Pb-labelled PSMA ligands: bringing the lead into PSMA-targeted alpha therapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1081-1091.	3.3	77
67	Biochemical Recurrence of Prostate Cancer: Initial Results with [¹⁸ F]PSMA-1007 PET/CT. <i>Journal of Nuclear Medicine</i> , 2018, 59, 632-635.	2.8	55
68	A Convenient Synthesis for HBED-CC-tris(tert-butyl ester). <i>Synlett</i> , 2018, 29, 1239-1243.	1.0	9
69	Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1179-1187.	3.3	26
70	Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined ¹⁸ F-FDG and ¹⁸ F-FLT PET/CT imaging. <i>EJNMMI Research</i> , 2018, 8, 28.	1.1	17
71	Monomeric and Dimeric ⁶⁸ Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPrs). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 2062-2074.	2.9	27
72	Cytochrome b 5 impacts on cytochrome P450-mediated metabolism of benzo[a]pyrene and its DNA adduct formation: studies in hepatic cytochrome b 5/P450 reductase null (HBRN) mice. <i>Archives of Toxicology</i> , 2018, 92, 1625-1638.	1.9	26

#	ARTICLE	IF	CITATIONS
73	68Ga-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 904-912.	3.3	34
74	Intraindividual Comparison of ¹⁸ F-PSMA-1007 and ¹⁸ F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1076-1080.	2.8	140
75	[18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 111-113.	0.9	4
76	Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 103-105.	0.9	4
77	Simultaneous whole-body 18F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 340-347.	3.3	32
78	PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 639-645.	2.8	89
79	Repeated ¹⁷⁷ Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. <i>Journal of Nuclear Medicine</i> , 2018, 59, 459-465.	2.8	68
80	Synthesis, radiosynthesis, in vitro and first in vivo evaluation of a new matrix metalloproteinase inhibitor based on ¹³ I-fluorinated \pm -sulfonylamino hydroxamic acid. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2018, 3, 10.	1.8	7
81	Imaging and radiotherapy for recurrent prostate cancer: An evolutionary partnership. <i>Radiotherapy and Oncology</i> , 2018, 129, 387-388.	0.3	1
82	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2045-2054.	3.3	116
83	Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 351-359.	1.0	9
84	18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e497-e499.	0.9	47
85	The Clinical Impact of Additional Late PET/CT Imaging with ⁶⁸ Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 750-755.	2.8	105
86	68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1014-1024.	3.3	589
87	⁶⁸ Ga or ¹⁸ F for Prostate Cancer Imaging?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 687-688.	2.8	105
88	Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1258-1268.	3.3	425
89	Intraindividual Comparison of ¹⁸ F-PSMA-1007 PET/CT, Multiparametric MRI, and Radical Prostatectomy Specimens in Patients with Primary Prostate Cancer: A Retrospective, Proof-of-Concept Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1805-1810.	2.8	91
90	Radiolabeled Selective Matrix Metalloproteinase 13 (MMP-13) Inhibitors: (Radio)Syntheses and in Vitro and First in Vivo Evaluation. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 307-321.	2.9	19

#	ARTICLE	IF	CITATIONS
91	Effects of arm truncation on the appearance of the halo artifact in ⁶⁸ Ga-PSMA-11 (HBED-CC) PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1636-1646.	3.3	17
92	Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in ⁶⁸ Ga-PSMA-11-PET of PET/CT and PET/MRI: comparison with mpMRI integrated in simultaneous PET/MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 776-787.	3.3	124
93	Improved clinical workflow for simultaneous whole-body PET/MRI using high-resolution CAIPIRINHA-accelerated MR-based attenuation correction. <i>European Journal of Radiology</i> , 2017, 96, 12-20.	1.2	24
94	Glu-Ureido- α -Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. <i>Journal of Nuclear Medicine</i> , 2017, 58, 17S-26S.	2.8	111
95	Identification of Ligands and Translation to Clinical Applications. <i>Journal of Nuclear Medicine</i> , 2017, 58, 27S-33S.	2.8	16
96	Comparison of human cytochrome P450 1A1-catalysed oxidation of benzo[a]pyrene in prokaryotic and eukaryotic expression systems. <i>Monatshefte für Chemie</i> , 2017, 148, 1959-1969.	0.9	10
97	Improving the Imaging Contrast of ⁶⁸ Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. <i>Bioconjugate Chemistry</i> , 2017, 28, 2485-2492.	1.8	40
98	Reply: PSMA Ligands for Imaging Prostate Cancer: Alternative Labeling by Complex Formation with Al ^{18F} F ²⁺ . <i>Journal of Nuclear Medicine</i> , 2017, 58, 2041-2041.	2.8	1
99	⁶⁸ Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1949-1955.	2.8	27
100	Preclinical Evaluation of ^{18F} -PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging. <i>Journal of Nuclear Medicine</i> , 2017, 58, 425-431.	2.8	186
101	Treatment response evaluation with ^{18F} -FDG PET/CT and ^{18F} -NaF PET/CT in multiple myeloma patients undergoing high-dose chemotherapy and autologous stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 50-62.	3.3	37
102	Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by aristolochic acids and 3-nitrobenzanthrone. <i>Archives of Toxicology</i> , 2017, 91, 1957-1975.	1.9	22
103	^{18F} -labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 678-688.	3.3	421
104	Clinical Translation and First In-Human Use of [⁴⁴ Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer. <i>Theranostics</i> , 2017, 7, 4359-4369.	4.6	94
105	Syntheses of Radioiodinated Pyrimidine-2,4,6-Triones as Potential Agents for Non-Invasive Imaging of Matrix Metalloproteinases. <i>Pharmaceuticals</i> , 2017, 10, 49.	1.7	7
106	Procedures for the GMP-Compliant Production and Quality Control of [^{18F}]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. <i>Pharmaceuticals</i> , 2017, 10, 77.	1.7	83
107	Radiolabeled prostate-specific membrane antigen small-molecule inhibitors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 61, 168-180.	0.4	19
108	Investigation of the halo-artifact in ⁶⁸ Ga-PSMA-11-PET/MRI. <i>PLoS ONE</i> , 2017, 12, e0183329.	1.1	53

#	ARTICLE	IF	CITATIONS
109	Carbon ion radiotherapy: impact of tumor differentiation on local control in experimental prostate carcinomas. <i>Radiation Oncology</i> , 2017, 12, 174.	1.2	18
110	Integration of CT urography improves diagnostic confidence of 68Ga-PSMA-11 PET/CT in prostate cancer patients. <i>Cancer Imaging</i> , 2017, 17, 30.	1.2	8
111	Role of Radiolabelled Small Molecules Binding to PSMA in Diagnosis and Therapy of Prostate Cancer. , 2017, , 51-58.		1
112	Abstract 3719: Bicyclic peptides for PET imaging of MT1-MMP expressing tumors. , 2017, , .		0
113	Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeutics. <i>Theranostics</i> , 2016, 6, 1085-1095.	4.6	60
114	68Ga-PSMA-11 Dynamic PET/CT Imaging in Primary Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2016, 41, e473-e479.	0.7	86
115	Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1400-1406.	3.3	101
116	The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 79S-89S.	2.8	200
117	Future trends in prostate cancer theranostics with PSMA ligands. <i>Clinical and Translational Imaging</i> , 2016, 4, 487-489.	1.1	6
118	Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 405-418.	2.5	72
119	²²⁵ Ac-PSMA-617 for PSMA-Targeted α -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1941-1944.	2.8	741
120	NADH:Cytochrome <i>b</i> ₅ Reductase and Cytochrome <i>b</i> ₅ Can Act as Sole Electron Donors to Human Cytochrome P450 1A1-Mediated Oxidation and DNA Adduct Formation by Benzo[<i>a</i>]pyrene. <i>Chemical Research in Toxicology</i> , 2016, 29, 1325-1334.	1.7	31
121	Imaging matrix metalloproteinase activity in multiple sclerosis as a specific marker of leukocyte penetration of the blood-brain barrier. <i>Science Translational Medicine</i> , 2016, 8, 364ra152.	5.8	94
122	Epoxyeicosatrienoic acids (EETs) form adducts with DNA in vitro. <i>Prostaglandins and Other Lipid Mediators</i> , 2016, 123, 63-67.	1.0	1
123	Radiation dosimetry of 68Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1611-1620.	3.3	143
124	Robust augmented reality guidance with fluorescent markers in laparoscopic surgery. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2016, 11, 899-907.	1.7	29
125	¹⁸ F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1929-1930.	3.3	81
126	The impact of p53 on DNA damage and metabolic activation of the environmental carcinogen benzo[<i>a</i>]pyrene: effects in Trp53(+/+), Trp53(+/-) and Trp53(~/~) mice. <i>Archives of Toxicology</i> , 2016, 90, 839-851.	1.9	36

#	ARTICLE	IF	CITATIONS
127	68Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1288-1299.	3.3	58
128	PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ¹⁷⁷ Lu-Labeled PSMA-617. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1170-1176.	2.8	475
129	Radiolabeled hydroxamate-based matrix metalloproteinase inhibitors: How chemical modifications affect pharmacokinetics and metabolic stability. <i>Nuclear Medicine and Biology</i> , 2016, 43, 424-437.	0.3	9
130	Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1673-1683.	3.3	13
131	Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts by carcinogenic aristolochic acid I in rats in vivo. <i>Toxicology</i> , 2016, 344-346, 7-18.	2.0	22
132	Linker Modification Strategies To Control the Prostate-Specific Membrane Antigen (PSMA)-Targeting and Pharmacokinetic Properties of DOTA-Conjugated PSMA Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1761-1775.	2.9	150
133	Novel Bispecific PSMA/GRPr Targeting Radioligands with Optimized Pharmacokinetics for Improved PET Imaging of Prostate Cancer. <i>Bioconjugate Chemistry</i> , 2016, 27, 737-751.	1.8	48
134	New Strategies in Prostate Cancer: Prostate-Specific Membrane Antigen (PSMA) Ligands for Diagnosis and Therapy. <i>Clinical Cancer Research</i> , 2016, 22, 9-15.	3.2	155
135	Positron Emission Tomography-computed Tomography with Prostate-specific Membrane Antigen Ligands as a Promising Tool for Imaging of Prostate Cancer. <i>European Urology</i> , 2016, 69, 397-399.	0.9	10
136	68Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 34-41.	3.3	194
137	Comparison of hybrid 68Ga-PSMA PET/MRI and 68Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 70-83.	3.3	148
138	Dosimetry for ¹⁷⁷ Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 42-51.	3.3	244
139	New matrix metalloproteinase inhibitors based on ¹⁸ F-fluorinated α -aminocarboxylic and α -aminohydroxamic acids. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 3809-3818.	1.4	18
140	Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists. <i>Organic and Biomolecular Chemistry</i> , 2015, 13, 2407-2422.	1.5	14
141	PMPA for Nephroprotection in PSMA-Targeted Radionuclide Therapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 293-298.	2.8	100
142	Novel fluorine-18 labeled 5-(1-pyrrolidinylsulfonyl)-7-azaisatin derivatives as potential PET tracers for in vivo imaging of activated caspases in apoptosis. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5734-5739.	1.4	8
143	Multimodal Imaging Reveals Temporal and Spatial Microglia and Matrix Metalloproteinase Activity after Experimental Stroke. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 1711-1721.	2.4	62
144	PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸ Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1794-1800.	3.3	109

#	ARTICLE	IF	CITATIONS
145	Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 914-920.	2.8	451
146	[¹⁷⁷ Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 987-988.	3.3	155
147	MP53-08 THE DIAGNOSTIC VALUE OF ⁶⁸ GA-LABELLED PSMA-LIGAND PET/CT IN MEN WITH RECURRENT PROSTATE CANCER. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
148	The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1697-1705.	2.8	332
149	The diagnostic value of PET/CT imaging with the ⁶⁸ Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 197-209.	3.3	866
150	Preclinical evaluation of a bispecific low-molecular heterodimer targeting both PSMA and GRPR for improved PET imaging and therapy of prostate cancer. <i>Prostate</i> , 2014, 74, 659-668.	1.2	93
151	Novel Preclinical and Radiopharmaceutical Aspects of [⁶⁸ Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. <i>Pharmaceuticals</i> , 2014, 7, 779-796.	1.7	323
152	Pharmaceuticals—Special Issue on Radiopharmaceutical Chemistry between Imaging and Endoradiotherapy. <i>Pharmaceuticals</i> , 2014, 7, 839-849.	1.7	2
153	Radiation dosimetry and first therapy results with a ¹²⁴ I/ ¹³¹ I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1280-1292.	3.3	319
154	PET/CT studies of multiple myeloma using ¹⁸ F-FDG and ¹⁸ F-NaF: comparison of distribution patterns and tracers' pharmacokinetics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1343-1353.	3.3	55
155	Mechanistic and high-throughput approaches for the design of molecular imaging probes and targeted therapeutics. <i>Clinical and Translational Imaging</i> , 2014, 2, 33-41.	1.1	1
156	Diverse modifications of the 4-methylphenyl moiety of TAK-779 by late-stage Suzuki-Miyaura cross-coupling. <i>Organic and Biomolecular Chemistry</i> , 2014, 12, 177-186.	1.5	8
157	Synthesis of 7-Halogenated Isatin Sulfonamides: Nonradioactive Counterparts of Caspase-3/-7 Inhibitor-Based Potential Radiopharmaceuticals for Molecular Imaging of Apoptosis. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9383-9395.	2.9	13
158	Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by ³ H-Deoxy- ³ H- ¹⁸ F-Fluorothymidine PET and Diffusion-Weighted MR Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 983-988.	2.8	21
159	Influence of 4- or 5-substituents on the pyrrolidine ring of 5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatin derivatives on their inhibitory activities towards caspases-3 and -7. <i>European Journal of Medicinal Chemistry</i> , 2013, 64, 562-578.	2.6	8
160	Inverse 1,2,3-Triazole-1-yl-ethyl Substituted Hydroxamates as Highly Potent Matrix Metalloproteinase Inhibitors: (Radio)synthesis, in Vitro and First in Vivo Evaluation. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6858-6870.	2.9	34
161	Non-peptidyl ¹⁸ F-Labelled PET Tracers as Radioindicators for the Noninvasive Detection of Cancer. <i>Recent Results in Cancer Research</i> , 2013, 187, 107-132.	1.8	2
162	Synthesis of new fluorinated, 2-substituted 5-pyrrolidinylsulfonyl isatin derivatives as caspase-3 and caspase-7 inhibitors: Nonradioactive counterparts of putative PET-compatible apoptosis imaging agents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 2025-2036.	1.4	23

#	ARTICLE	IF	CITATIONS
163	Synthesis, ¹⁸ F-Radiolabeling, and in Vivo Biodistribution Studies of N-Fluorohydroxybutyl Isatin Sulfonamides using Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 4509-4520.	2.9	11
164	A Closer Look at the Bromine- ⁶ Lithium Exchange with <i>tert</i> -Butyllithium in an Aryl Sulfonamide Synthesis. <i>Organic Letters</i> , 2013, 15, 2954-2957.	2.4	45
165	Early Assessment of the Efficacy of Temozolomide Chemotherapy in Experimental Glioblastoma Using [¹⁸ F]FLT-PET Imaging. <i>PLoS ONE</i> , 2013, 8, e67911.	1.1	32
166	Synthesis and in vivo evaluation of an (¹⁸ F)-labeled glycoconjugate of PD156707 for imaging ETA receptor expression in thyroid carcinoma by positron emission tomography. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2013, 3, 425-36.	1.0	5
167	A New Class of Highly Potent Matrix Metalloproteinase Inhibitors Based on Triazole-Substituted Hydroxamates: (Radio)Synthesis and in Vitro and First in Vivo Evaluation. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 4714-4727.	2.9	43
168	Radiosynthesis of a ⁶⁸ Ga labeled matrix metalloproteinase inhibitor as a potential probe for PET imaging. <i>Applied Radiation and Isotopes</i> , 2012, 70, 1723-1728.	0.7	6
169	Efficient synthesis of a fluorine-18 labeled biotin derivative. <i>Nuclear Medicine and Biology</i> , 2012, 39, 1189-1194.	0.3	6
170	A New Generation of Radiofluorinated Pyrimidine-2,4,6-triones as MMP-Targeted Radiotracers for Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 223-232.	2.9	49
171	Metabolite Identification of a Radiotracer by Electrochemistry Coupled to Liquid Chromatography with Mass Spectrometric and Radioactivity Detection. <i>Analytical Chemistry</i> , 2011, 83, 5415-5421.	3.2	29
172	Development and Evaluation of Endothelin-A Receptor (Radio)Ligands for Positron Emission Tomography. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 939-948.	2.9	17
173	The MMP inhibitor (R)-2-(N-benzyl-4-(2-[¹⁸ F]fluoroethoxy)phenylsulphonamido)-N-hydroxy-3-methylbutanamide: Improved precursor synthesis and fully automated radiosynthesis. <i>Applied Radiation and Isotopes</i> , 2011, 69, 862-868.	0.7	26
174	Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments. <i>British Journal of Radiology</i> , 2011, 84, S168-S178.	1.0	2
175	Radiofluorinated Pyrimidine-2,4,6-triones as Molecular Probes for Noninvasive MMP-Targeted Imaging. <i>ChemMedChem</i> , 2010, 5, 777-789.	1.6	59
176	Molecular Imaging of Cardiac Sympathetic Innervation by ¹¹ C- <i>m</i> -HED and PET: From Man to Mouse?. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1269-1276.	2.8	22
177	Synthesis of Geminal Difluorides by Oxidative Desulfurization~Difluorination of Alkyl Aryl Thioethers with Halonium Electrophiles in the Presence of Fluorinating Reagents and Its Application for ¹⁸ F-Radiolabeling. <i>Journal of Organic Chemistry</i> , 2010, 75, 6086-6095.	1.7	15
178	Preclinical evaluation of an ¹⁸ F-labelled ¹²⁵ I-adrenoceptor selective radioligand based on ICI 89,406. <i>Nuclear Medicine and Biology</i> , 2010, 37, 517-526.	0.3	12
179	Encapsulating ¹¹¹ In in Nanocontainers for Scintigraphic Imaging: Synthesis, Characterization, and In Vivo Biodistribution. <i>ACS Nano</i> , 2010, 4, 342-348.	7.3	82
180	Biodistribution of a Nonpeptidic Fluorescent Endothelin a Receptor Imaging Probe. <i>Molecular Imaging</i> , 2009, 8, 7290.2009.00003.	0.7	15

#	ARTICLE	IF	CITATIONS
181	Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2009, 9, 968-985.	0.9	23
182	Fluorinated isatin derivatives. Part 1: Synthesis of new N-substituted (S)-5-[1-(2-methoxymethylpyrrolidinyl)sulfonyl]isatins as potent caspase-3 and -7 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 2680-2688.	1.4	48
183	PET-compatible endothelin receptor radioligands: Synthesis and first in vitro and in vivo studies. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 7197-7208.	1.4	11
184	A new 18F-labelled derivative of the MMP inhibitor CGS 27023A for PET: Radiosynthesis and initial small-animal PET studies. <i>Applied Radiation and Isotopes</i> , 2009, 67, 606-610.	0.7	60
185	Synthesis and Evaluation of a Novel Hydroxamate Based Fluorescent Photoprobe for Imaging of Matrix Metalloproteinases. <i>Bioconjugate Chemistry</i> , 2009, 20, 904-912.	1.8	32
186	Fluorinated Isatin Derivatives. Part 2. New N-Substituted 5-Pyrrolidinylsulfonyl Isatins as Potential Tools for Molecular Imaging of Caspases in Apoptosis. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 3484-3495.	2.9	71
187	Fluorinated isatin derivatives. Part 3. New side-chain fluoro-functionalized pyrrolidinyl sulfonyl isatins as potent caspase-3 and -7 inhibitors. <i>Future Medicinal Chemistry</i> , 2009, 1, 969-989.	1.1	19
188	Non-Invasive Approaches to Visualize the Endothelin Axis In Vivo Using State-of-the-Art Molecular Imaging Modalities. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 1580-1595.	1.1	2
189	Are [O-methyl-11C]derivatives of ICI 89,406 β 1-adrenoceptor selective radioligands suitable for PET?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 174-185.	3.3	7
190	18F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases. <i>Basic Research in Cardiology</i> , 2008, 103, 131-143.	2.5	11
191	Characterization of 3-[123I]iodo-L \pm -methyl tyrosine transport in astrocytes of neonatal rats. <i>Journal of Neurochemistry</i> , 2008, 76, 97-104.	2.1	11
192	18F-Labelled PET Tracers for Cardiological Imaging. , 2008, , 85-139.		1
193	Synthesis and Evaluation of a Novel Fluorescent Photoprobe for Imaging Matrix Metalloproteinases. <i>Bioconjugate Chemistry</i> , 2008, 19, 1001-1008.	1.8	51
194	β 1-Adrenoceptors in Rat Anterior Pituitary May Be Constitutively Active. Inverse Agonism of CGP 20712A on Basal β 2-Cyclic Adenosine 5'-Monophosphate Levels. <i>Endocrinology</i> , 2008, 149, 2391-2402.	1.4	8
195	A Fluorescent Photoprobe for the Imaging of Endothelin Receptors. <i>Bioconjugate Chemistry</i> , 2007, 18, 685-694.	1.8	27
196	Novel Fluorinated Derivatives of the Broad-Spectrum MMP Inhibitors N-Hydroxy-2-[[[4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as Potential Tools for the Molecular Imaging of Activated MMPs with PET. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 5752-5764.	2.9	68
197	Molecular cardiovascular imaging using scintigraphic methods. <i>European Radiology</i> , 2007, 17, 1422-1432.	2.3	9
198	Targeting of matrix metalloproteinase activation for noninvasive detection of vulnerable atherosclerotic lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007, 34, 1-8.	3.3	39

#	ARTICLE	IF	CITATIONS
199	Synthesis, in vitro pharmacology and biodistribution studies of new PD 156707-derived ETA receptor radioligands. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 1910-1917.	1.4	13
200	5-Pyrrolidinylsulfonfyl Isatins as a Potential Tool for the Molecular Imaging of Caspases in Apoptosis. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 6704-6715.	2.9	63
201	Synthesis of an ^{18}F -labelled high affinity ^{125}I -adrenoceptor PET radioligand based on ICI 89,406. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2006, 49, 177-195.	0.5	11
202	Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET. <i>Current Medicinal Chemistry</i> , 2006, 13, 2819-2838.	1.2	84
203	Whole-body PET/CT with ^{11}C -meta-hydroxyephedrine in tumors of the sympathetic nervous system: feasibility study and comparison with ^{123}I -MIBG SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1635-42.	2.8	69
204	Synthesis of (R)- and (S)-[O-methyl- ^{11}C]N-[2-[3-(2-cyano-phenoxy)-2-hydroxy-propylamino]-ethyl]-N $^{\epsilon}$ -(4-methoxy-phenyl)-urea as candidate high affinity ^{125}I -adrenoceptor PET radioligands. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2005, 48, 721-733.	0.5	7
205	Non-Invasive Molecular Imaging of α_1 -Adrenoceptors In Vivo: Perspectives for PET-Radioligands. <i>Current Medicinal Chemistry</i> , 2005, 12, 2057-2074.	1.2	30
206	C-5-Disubstituted Barbiturates as Potential Molecular Probes for Noninvasive Matrix Metalloproteinase Imaging. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3400-3409.	2.9	58
207	Scintigraphic Imaging of Matrix Metalloproteinase Activity in the Arterial Wall In Vivo. <i>Circulation</i> , 2004, 109, 2554-2559.	1.6	211
208	Early Effects of Irradiation on [^{123}I]-IMT and [^{18}F]-FDG Uptake in Rat C6 Glioma Cells. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 434-441.	1.0	10
209	Synthesis and first in vivo evaluation of new selective high affinity ^{125}I -adrenoceptor radioligands for SPECT based on ICI 89,406. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 4117-4132.	1.4	14
210	Synthesis and preliminary biological evaluation of new radioiodinated MMP inhibitors for imaging MMP activity in vivo. <i>Nuclear Medicine and Biology</i> , 2004, 31, 257-267.	0.3	72
211	Design of new ^{125}I -selective adrenoceptor ligands as potential radioligands for in vivo imaging. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 3513-3527.	1.4	26
212	Prognostic Significance of Amino Acid Transport Imaging in Patients with Brain Tumors. <i>Neurosurgery</i> , 2002, 50, 958-965.	0.6	0
213	Prognostic Significance of Amino Acid Transport Imaging in Patients with Brain Tumors. <i>Neurosurgery</i> , 2002, 50, 958-965.	0.6	10
214	Current status and future applications of cardiac receptor imaging with positron emission tomography. <i>Nuclear Medicine Communications</i> , 2002, 23, 113-115.	0.5	9
215	3-[^{123}I]iodo-L- $^{\alpha}$ -methyl tyrosine transport into human fibroblasts and comparison with Ewing's sarcoma cells. <i>Nuclear Medicine and Biology</i> , 2002, 29, 483-490.	0.3	2
216	Characterization of 3-[^{123}I]iodo-L- $^{\alpha}$ -methyl tyrosine ([^{123}I]IMT) transport into human Ewing's sarcoma cells in vitro. <i>Nuclear Medicine and Biology</i> , 2001, 28, 123-128.	0.3	11

#	ARTICLE	IF	CITATIONS
217	Kinetic parameters of 3-[¹²³ I]iodo-L-tyrosine ([¹²³ I]IMT) transport in human GOS3 glioma cells. Nuclear Medicine and Biology, 2001, 28, 293-297.	0.3	20
218	Sequential scintigraphic strategy for the differentiation of brain tumours. European Journal of Nuclear Medicine and Molecular Imaging, 2000, 27, 550-558.	3.3	27
219	Kinetics of 3-[¹²³ I]iodo-L-tyrosine transport in rat C6 glioma cells. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1274-1278.	2.2	22
220	Kinetics of 3-[¹²³ I]iodo-L-tyrosine transport in rat C6 glioma cells. European Journal of Nuclear Medicine and Molecular Imaging, 1999, 26, 1274.	2.2	9
221	Ein zweikerniger Vanadium(V)-Komplex mit (1/4 ¹)- und (1/4 ²)-gebundenen Hydrazido(2-)-Liganden / A Dinuclear Vanadium(V) Complex with (1/4 ¹)- and (1/4 ²)-Bonded Hydrazido(2-) Ligands. Zeitschrift Für Naturforschung - Section B Journal of Chemical Sciences, 1996, 51, 1675-1678.	0.3	9
222	Novel radiolabeled silicon rhodamine dyes for bimodal scintigraphic and optical imaging. , 0, , .		1
223	Procedures for the GMP-Compliant Production and Quality Control of [¹⁸ F]PSMA-1007: A Next Generation Radiofluorinated Tracer for the Detection of Prostate Cancer. , 0, , .		0
224	Clickable albumin binders to modulate pharmacokinetic properties of theranostic radioligands. , 0, , .		0
225	Barium-131 as starting point for the development of radiotheranostic approaches. , 0, , .		0